Suppression of dsDNA-specific B lymphocytes reduces disease symptoms in SCID model of mouse lupus

References

• Tchorbanov, A., E. Voynova, N. Mihaylova, et al. 2007. Selective silencing of DNA-specific B lymphocytes delays lupus activity in MRL/lpr mice. Eur. J. Immunol. 37: 3587–3596
   PubMed Web of Science ®Google Scholar
• Ehrenstein, M., D. Katz, M. Griffiths, et al. 1995. Human IgG anti-DNA antibodies deposit in kidneys and induce proteinuria in SCID mice. Kidney Int. 48: 705–711
   PubMed Web of Science ®Google Scholar
• Mason, L., C. Ravirajan, D. Latchman, and D. Isenberg. 2001. A human anti-dsDNA monoclonal antibody caused hyaline thrombi formation in kidneys of “leaky” SCID mice. Clin. Exp. Immunol. 126: 137–142
   PubMed Web of Science ®Google Scholar
• Kalsi, J. K., A. C. Martin, Y. Hirabayashi, et al. 1996. Functional and modelling studies of the binding of human monoclonal anti-DNA antibodies to DNA. Mol. Immunol. 33: 471–483
   PubMed Web of Science ®Google Scholar
• Shlomchik, M. J., M. P. Madaio, D. Ni, et al. 1994. The role of B cells in lpr/lpr-induced autoimmunity. J. Exp. Med. 180: 1295–1306
   PubMed Web of Science ®Google Scholar
• Chan, O. T., L. G. Hannum, A. M. Haberman, et al. 1999. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J. Exp. Med. 189: 1639–1648
   PubMed Web of Science ®Google Scholar
• Freed, J., A. Marrs, J. Vander Wall, et al. 2000. MHC Class II-bound self peptides from autoimmune MRL/lpr mice reveal potential T cell epitopes for autoantibody production in murine Systemic Lupus Erythematosus. J. Immunol. 164: 4697–4705
   PubMed Web of Science ®Google Scholar
• Foster, M. 2007. T cells and B cells in lupus nephritis. Semin. Nephrol. 27: 47–58
   PubMed Web of Science ®Google Scholar
• Ahuja, A., J. Shupe, R. Dunn, et al. 2007. Depletion of B cells in murine lupus: efficacy and resistance. J. Immunol. 179: 3351–3361
   PubMed Web of Science ®Google Scholar
• Looney, J., J. Anolik, D. Campbell, et al. 2004. B cell depletion as a novel treatment for systemic lupus erythematosus. Arthritis Rheum. 50: 2580–2589
   PubMed Web of Science ®Google Scholar
• Bouaziz, J. D., K. Yanada, G. M. Venturi, et al. 2007. Therapeutic B cell depletion impaires adaptive and autoreactive CD4+ T cell activation in mice. PNAS. 104: 20878–20883
   PubMed Web of Science ®Google Scholar
• Gorman, C., M. Leandro, and D. Isenberg. 2003. B cell depletion in autoimmune disease. Arthritis Res. Ther. 5: S17–S21
   PubMed Web of Science ®Google Scholar
• Ravetch, J. V., and L. L. Lanier. 2000. Immune inhibitory receptors. Science. 290: 84–89
   PubMed Web of Science ®Google Scholar
• Tarasenko, T., J. A. Dean, and S. Boland. 2007. FcγRIIb as a modulator of autoimmune disease susceptibility. Autoimmunity. 40: 409–417
   PubMed Web of Science ®Google Scholar
• Venkatesh, J., D. Kawabata, S. Kim, et al. 2009. Selective regulation of autoreactive B cells by FcγRIIb. J. Autoimmun. 32: 149–157
   PubMed Web of Science ®Google Scholar
• Xiang, Z., A. Cutler, R. Brownlie, et al. 2007. FcγRIIb controls bone marrow plasma cell persistence and apoptosis. Nat. Immunol. 8: 419–429
   PubMed Web of Science ®Google Scholar
• Nimmerjahn, F., and J. Ravetch. 2007. The anti-inflammatory activity of IgG: the intravenous IgG paradox. J. Exp. Med. 204: 11–15
   PubMed Web of Science ®Google Scholar
• Shoenfeld, Y., L. Rauova, B. Gilburd, et al. 2002. Efficacy of IVIG affinity-purified anti-double-stranded DNA anti-idiotipic antibodies in the treatment of an experimental murine model of systemic lupus erythematosus. Intern. Immunol. 14: 1303–1311
   PubMed Web of Science ®Google Scholar
• Kaneko, Y., F. Nimmerjahn, M. P. Madaio, and J. V. Ravetch. 2006. Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. J. Exp. Med. 203: 789–797
   PubMed Web of Science ®Google Scholar
• Samuelsson, A., T. Towers, and J. Ravetch. 2001. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptors. Science. 291: 484–486
   PubMed Web of Science ®Google Scholar
• Nikolova, K., A. Tchorbanov, I. Djoumerska-Alexieva, et al. 2009. Intravenous immunoglobulin up-regulates the expression of the inhibitory FcγIIB receptor on B cells. Immunol. Cell. Biol. 87: 529–533
   PubMed Web of Science ®Google Scholar
• Huston, D., and A. Steinberg. 1979. Animal models of human systemic lupus erythematosus. Yale J. Biol. Med. 52: 289–305
   PubMed Web of Science ®Google Scholar
• Chan, O., and M. Shlomchik. 1998. A new role for B cells in systemic autoimmunity: B cells promote spontaneous T cell activation in MRL-lpr/lpr mice. J. Immunol. 160: 51–59
   PubMed Web of Science ®Google Scholar
• Dong, J., Q-X. Wang, C-Y. Zhou, et al. 2007. Activation of the STAT1 signalling pathway in lupus nephritis in MRL/lpr mice. Lupus. 6: 101–109
   Google Scholar
• Takeuchi, K., M. Inada, S. Miyashima, et al. 1998. A new strategy for treatment of autoimmune diseases in chimeric resistant MRL/lpr mice. Blood. 12: 4616–4623
   Google Scholar
• Sthoeger, Z., H. Zinger, B. Dekel, et al. 2003. Lupus manifestation in severe combined immunodeficient (SCID) mice and in human/mouse radiation chimeras. J. Clin. Immunol. 23: 91–99
   PubMed Web of Science ®Google Scholar
• Vladutiu, A. 1993. The severe combined immunodeficient (SCID) mouse as a model for the study of autoimmune diseases. Clin. Exp. Immunol. 93: 1–8
   PubMed Web of Science ®Google Scholar
• Macchiarini, F., M. Manz, K. Palucka, and L. Shultz. 2005. Humanized mice: are we there yet? J. Exp. Med. 202: 1307–1311
   PubMedGoogle Scholar
• Iwai, H., K. Tomuda, N. Hosaka, et al. 1998. Induction of immune-mediated hearing loss in SCID mice by injection of MRL/lpr mouse spleen cells. Hear. Res. 117: 173–177
   PubMed Web of Science ®Google Scholar
• Wang, Y. H., and B. Diamond. 2008. B cell receptor revision diminishes the autoreactive B cell response after antigen activation in mice. J. Clin. Invest. 118: 2896–2907
   PubMed Web of Science ®Google Scholar
• Putterman, C., B. Deocharan, and B. Diamond. 2000. Molecular analysis of the autoantibody response in peptide-induced autoimmunity. J. Immunol. 164: 2542–2549
   PubMed Web of Science ®Google Scholar
• Bauminger, S., and M. Wilchek. 1980. The use of carbodiimides in the preparation of immunizing conjugates. Methods Enzymol. 70: 151–159
   PubMedGoogle Scholar
• Mihaylova, N., E. Voynova, A. Tchorbanov, et al. 2009. Simultaneous engagement of FcγIIb and CD22 inhibitory receptors suppresses the activity of targeted autoreactive B cells. Mol. Immunol. 47: 123–130
   PubMed Web of Science ®Google Scholar
• Bobe, P., D. Bonardelle, K. Benihoud, et al. 2006. Arsenic trioxide: a promising novel therapeutic agent for lymphoproliferative and autoimmune syndromes in MRL/lpr mice. Blood. 108: 3967–3975
   PubMed Web of Science ®Google Scholar
• Anolik, J. 2007. B cell biology and disfunction in SLE. Bull. NYU Hosp. Jt. Dis. 65: 182–186
   PubMedGoogle Scholar
• Hoyer, B. F., K. Moser, A. F. Hauser, et al. 2004. Short-lived plasmablasts and long-lived plasma cells contribute to chronic humoral autoimmunity in NZB/W mice. J. Exp. Med. 199: 1577–1584
   PubMed Web of Science ®Google Scholar
• Dörner, T., J. Kaufmann, W. Wegener, et al. 2006. Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res. Ther. 8: R74–R84
   PubMed Web of Science ®Google Scholar
• Yazawa, N., Y. Hamaguchi, J. Poe, and T. Tedder. 2005. Immunotherapy using unconjugated CD19 monoclonal antibodies in animal models for B lymphocyte malignancies and autoimmune disease. PNAS. 102: 15178–15183
   PubMed Web of Science ®Google Scholar
• Daëron, M., and R. Lesourne. 2006. Negative signaling in Fc receptor complexes. Adv. Immunol. 89: 39–86
   PubMed Web of Science ®Google Scholar
• Nimmerjahn, F., and J. V. Ravetch. 2006. Fcgamma receptors: old friends and new family members. Immunity. 24: 19–28
   PubMed Web of Science ®Google Scholar
• Kerekov N., N. Mihaylova, I. Grozdev, et al. 2011. Elimination of autoreactive B cells in humanized SCID mouse model of SLE. Eur. J. Immunol. 41: 3301–3311
   PubMed Web of Science ®Google Scholar
• Mihaylova, N., E. Voynova, A. Tchorbanov, et al. 2008. Selective silencing of disease-associated B-lymphocytes by chimeric molecules targeting their Fc gamma IIb receptor. Int. Immunol. 20: 165–175
   PubMed Web of Science ®Google Scholar
• Kaliyaperumal, A., M. A. Michaels, and S. K. Datta. 1999. Antigen-specific therapy of murine lupus nephritis using nucleosomal peptides: tolerance spreading impairs pathogenic function of autoimmune T and B cells. J. Immunol. 162: 5775–5783
   PubMed Web of Science ®Google Scholar
• Mohan, C., S. Adams, V. Stanik, and S. Datta. 1993. Nucleosome: a major immunogen for pathogenic autoantibody-inducing T cells of lupus. J. Exp. Med. 177: 1367–1381
   PubMed Web of Science ®Google Scholar
• Clynes, R., N. Calvani, B. P. Crocer, and H. B. Richards. 2005. Modulation of the immune response in pristane-induced lupus by expression of activation and inhibitory Fc receptors. Clin. Exp. Immunol. 141: 230–237
   PubMed Web of Science ®Google Scholar
• Dimitrova, I., Gesheva, V., Nikolova, K., et al. 2010. Target silencing of disease-associated B-lymphocytes by chimeric molecules in SCID model of pristane-induced autoimmunity. Lupus. 19: 1261–1271
   PubMed Web of Science ®Google Scholar
• Duchosal, M., P. McConahey, C. Robinson, and F. Dixon. 1990. Transfer of human systemic lupus erythematosus in severe combined immunodeficient (SCID) mice. J. Exp. Med. 172: 985–988
   PubMed Web of Science ®Google Scholar
• Kidd, P. 2003. Th1/Th2 balance: the hypothesis, its limitations, and implications for health and disease. Altern. Med. Rev. 8: 223–246
   PubMedGoogle Scholar